Rousculp MD, Hollis K, Ziemiecki R, Odom D, Marchese AM, Montazeri M, Odak S, Jackson L, Miller A, Toback S. Burden and impact of reactogenicity among adults receiving COVID-19 vaccines in the United States and Canada: results from a prospective observational study. Vaccines (Basel). 2024 Jan 13;12(1):83. doi: 10.3390/vaccines12010083
Paret K, Beyhaghi H, Herring WL, Mauskopf J, Shane LG, Rousculp WD. Going forward: potential impact of protein-based COVID-19 vaccination coverage on population outcomes and costs in the United States. Vaccines (Basel). 2024 Jan 12;12(1):74. doi: 10.3390/vaccines12010074
Shamarina D, Sluga-O'Callaghan M, Kassianos G, Marijam A, Dave V, Davenport E, Andani A, Curran D, Dewda P, Steffen R. Knowledge, attitudes, and practices of European healthcare professionals towards hepatitis A and hepatitis B vaccination in at-risk adults. Vaccines (Basel). 2023 Oct 26;11(1645):1-19. doi: 10.3390/vaccines11111645
Wilson M, Lucas A, Mendes D, Vyse A, Mikudina B, Czudek C, Ellsbury GF, Perdrizet J. Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom. Vaccines (Basel). 2023 Jun 28;11(7):1168. doi: 10.3390/vaccines11071168
Saxena K, Sawhney B, Yande S, Kathe N, Chatterjee S. The burden of cervical conization in privately insured young and mid-adult women in the United States. Vaccines (Basel). 2023 Apr 5;11(4):804. doi: 10.3390/vaccines11040804
Masaquel C, Schley K, Wright K, Mauskopf J, Parrish RA, Presa JV, Hewlett, Jr. D. The impact of social determinants of health on meningococcal vaccination awareness, delivery, and coverage in adolescents and young adults in the United States: a systematic review. Vaccines (Basel). 2023 Jan 24;11(2):256. doi: 10.3390/vaccines11020256
Dubov A, Distelberg BJ, Abdul-Mutakabbir JC, Peteet B, Roberts L, Montgomery SB, Rockwood N, Patel P, Shoptaw S, Chrissian AA. Racial/ethnic variances in COVID-19 inoculation among southern California healthcare workers. Vaccines (Basel). 2022 Aug 17;10(8):1331. doi: 10.3390/vaccines10081331
Velardo F, Watson V, Arwidson P, Alla F, Luchini S, Schwarzinger M, CoVaMax Study Group. Regional differences in COVID-19 vaccine hesitancy in December 2020: a natural experiment in the French working-age population. Vaccines (Basel). 2021 Nov 20;9(11):1364. doi: 10.3390/vaccines9111364
Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.
Novick D, Reed C, Gonzalez-Pinto A, Aguado J, Haro JM. Comparison of olanzapine and valproate over 12 months of treatment in the emblem study. J Psychopharmacol. 2010;24:A54.
Chatzi L, Plana E, Pappas A, Alegkakis D, Karakosta P, Daraki V. The metabolic syndrome in early pregnancy and risk of gestational diabetes mellitus. Diabetes Metab. 2009 Dec;35(6):490-4.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. J Psychopharmacol. 2007;21(Suppl):A39.
Fireman B, Mines D, Lee J, Hunkeler EM. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Poster presented at the 2006 Summer Meeting of the British Association for Psychopharmacology; July 2006. Oxford, United Kingdom. [abstract] J Psychopharmacol. 2006 Sep; 20(5 Suppl):A58.
Heyes A. Clinical trial experience with Functional Assessment of Cancer Therapy—Lung in conventional and targeted non—small cell lung cancer therapy. Semin Oncol. 2004 Jun 1;31(Suppl. 9):16-22.